Table 3.
Outcomes after transplantation from HLA-matched unrelated donors as compared to HLA-identical sibling donors*
| MRD
N |
URD
N |
Overall mortality | Non-relapse mortality | Relapse / progression | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |||
| Univariate | 221 | 184 | 1.29 (1.0-1.7) | 0.08 | 1.22 (0.8-1.9) | 0.36 | 1.17 (0.9-1.6) | 0.32 |
| Multivariate* | 221 | 184 | 1.01 (0.7-1.4) | 0.95 | 0.98 (0.6-1.6) | 0.93 | 1.10 (0.8-1.6) | 0.60 |
| Comorbidity category: [34] | ||||||||
| HCT-CI 0 | 65 | 40 | 1.07 (0.5-2.3) | trend**
0.42 |
1.23 (0.3-4.4) | trend**
0.66 |
||
| HCT-CI 1-2 | 69 | 157 | 1.28 (0.7-2.2) | 1.03 (0.4-2.5) | ||||
| HCT-CI ≥3 | 87 | 87 | 0.87 (0.6-1.3) | 0.92 (0.5-1.7) | ||||
| Relapse risk category: [35] | ||||||||
| Low | 46 | 42 | 1.22 (0.6-2.5) | trend**
0.47 |
0.49 (0.2-1.2) | trend**
0.007 |
||
| Intermediate | 111 | 83 | 1.07 (0.7-1.7) | 0.85 (0.5-1.4) | ||||
| High | 64 | 59 | 0.91 (0.6-1.4) | 1.76 (1.1-2.9) | ||||
| Patient age: | ||||||||
| <50 years | 76 | 60 | 1.10 (0.6-1.9) | 0.70 | 0.65 (0.3-1.6) | 0.29 | 1.70 (1.0-3.0) | 0.06 |
| ≥50 years | 145 | 124 | 0.98 (0.7-1.4) | 1.11 (0.7-1.9) | 0.89 (0.6-1.4) | |||
*
Adjusted for patient age, HCT-CI, relapse risk category, use of fludarabine in the preparative regimen, donor/recipient sex-mismatch, stem cell source, prior cytomegalovirus-infection.
**
Test for trend across comorbidity or relapse risk groups in the relative difference between URD and MRD outcomes.
HR denotes hazard ratio; CI, confidence interval; MRD, HLA-identical sibling donor; URD, HLA-matched unrelated donor; HCT-CI, hematopoietic cell transplantation comorbidity index. A hazard ratio of >1.0 indicates a more favorable outcome with related donors.